<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDG

Brad Kline(University of California, San Francisco), Thomas A. Hope(University of California, San Francisco), Robin Kate Kelley(University of California, San Francisco), Spencer C. Behr(University of California, San Francisco), Courtney Lawhn-Heath(University of California, San Francisco), Robin Cumming Ippisch(University of California, San Francisco), Patrick K. Ha(University of California, San Francisco), Youngho Seo(University of California, San Francisco), Rahul Aggarwal(University of California, San Francisco), Robert R. Flavell(University of California, San Francisco), Sue S. Yom(University of California, San Francisco), Hope S. Rugo(University of California, San Francisco), Victoria Wang(University of California, San Francisco), Fei Jiang(University of California, San Francisco), Michelle Melisko(University of California, San Francisco), Surekha Yadav(University of California, San Francisco), Jessa B. Castillo(University of California, San Francisco)
Journal of Nuclear Medicine
May 2, 2024
10.2967/jnumed.123.267281
Cited by 36

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k